Literature DB >> 6825125

Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay.

W R Cobb, A E Bogden, S D Reich, T W Griffin, D E Kelton, D J LePage.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825125

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  The usefulness of cyclophosphamide pretreatment for subrenal capsule assay against human esophageal cancer.

Authors:  M Terashima; K Ikeda; S Kawamura; C Maesawa; K Ishida; M Sato; K Saito
Journal:  Jpn J Surg       Date:  1991-03

2.  Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assay.

Authors:  W R Cobb; A E Bogden; S D Reich; T W Griffin; D E Kelton; D J LePage
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

Authors:  K Hoffman; F A Holmes; G Fraschini; L Esparza; D Frye; M N Raber; R A Newman; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer.

Authors:  B C Behrens; T C Hamilton; K G Louie; K R Grotzinger; W M McKoy; T Tsuruo; R C Young; R F Ozols
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Brain tumor growth and response to chemotherapy in the subrenal capsule assay.

Authors:  M Weizsäcker; A Nagamune; K Rathmer; W Wechsler
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice.

Authors:  S Aamdal; O Fodstad; J M Nesland; A Pihl
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.